Clara, N. Soronnadi and Ibeh, N. C. and Ugwuene, F. O. and Maduka, L. and Odurukwe, O. and Aneke, E. I. and Ajuba, M. (2022) Use the Complete Blood Counts and Esr as Biomarkers Prognostic Tool in Breast Cancer Patients Attending Surgery Department at Esut Teaching Hospital, Parklane Enugu Nigeria. Journal of Pharmaceutical Research International, 34 (39A). pp. 6-29. ISSN 2456-9119
6353-Article Text-8567-2-10-20221006.pdf - Published Version
Download (652kB)
Abstract
Background: Full blood count is a prerequisite investigation requested from all breast cancer patients before and during treatment.Poor parameters adversely influence the outcome of cancers.
Objective: This study investigated the use of Complete Blood Count (CBC) and Erythrocyte Sedimentation Rate (ESR) as biomarker prognostic tool in breast cancer subjects.
Methods: The sample size comprised of 110 female subjects and controls with ages between 21-70 years. A longitudinal study method was used. The samples were collected from apparently healthy individuals as control, pre-treatment at diagnosis and the treatment samples at different stages of the treatment. Questionnaire used obtained other demographic information. The data was analyzed with IBM SPSS PC. Version 20.0; SPSS Inc., Chicago, III., USA.
Results: Results showed that increased Neutrophil/Lymphocyte Ratio (NLR) and decreased Lymphocyte / Monocyte Ratio (LMR) were significantly associated with increased hazard ratio (HR) and decreased OS at p<0.05 while Platelet/Lymphocyte Ratio ( PLR) had no significant difference at P>0.05 in Breast Cancer. In CBC and ESR, control, pre-treatment and treatment period, red blood cell (RBC) parameters and total white blood cell (TWBC) parameters decreased significantly at p<0.05 in treatment results compared to the pre-treatment and control results while others showed no significant increase at p<0.05 in treatment results compared to pre-treatment results. Treatment red cell distribution width (RDW) and mean platelet volume (MPV) observed a significant increase (p<0.05) compared to the control and pre-treatment results. Age group 21-30 years showed more susceptibility than other age groups with lowest mean±SD in CBC and ESR but with no significant difference at p>0.05.
Conclusion: This study supports the concept that biomarkers such as CBC and ESR can be used as a prognostic tool in early detection, treatment and monitoring of the disease progression in these subjects
Item Type: | Article |
---|---|
Subjects: | Institute Archives > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 25 Feb 2023 06:33 |
Last Modified: | 09 Mar 2024 03:59 |
URI: | http://eprint.subtopublish.com/id/eprint/1657 |